Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
In first-line NSCLC the drug beats chemo, and not Keytruda.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
